Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells

Biomaterials

Volumn 32, Issue 35, 2011, Pages 9483-9493

  Koirala, Adarsha ^a   Makkia, Rasha S ^a   Cooper, Mark J ^b   Naash, Muna I ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Copernicus Therapeutics Inc ^*  (United States)

Author keywords

DNA nanoparticle; Gene therapy; Polyethylene glycol (PEG); Retinal pigment epithelium; Subretinal injection

Indexed keywords

BALB/C MICE; DELETERIOUS EFFECTS; EXPRESSION LEVELS; NAKED DNA; PHOTORECEPTOR CELL; REPORTER VECTORS; RETINAL PIGMENT EPITHELIAL CELLS; RETINAL PIGMENT EPITHELIUM; RETINAL STRUCTURE; RETINITIS PIGMENTOSA; RPE CELL; SUBRETINAL INJECTION; TRANSFECTED CELLS; TRANSGENE EXPRESSION; VISUAL FUNCTIONS;

CELLS; DNA; GENE TRANSFER; GENES; GLYCOLS; MAMMALS; NANOPARTICLES; OPHTHALMOLOGY; POLYETHYLENE GLYCOLS;

ALDEHYDES;

DNA; DNA NANOPARTICLE; ENHANCED GREEN FLUORESCENT PROTEIN; NANOPARTICLE; RHODAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL FUNCTION; RETINAL PIGMENT EPITHELIAL CELL; RETINAL STRUCTURE;

ANIMALS; CHLORIDE CHANNELS; DNA; EPITHELIAL CELLS; EYE PROTEINS; FEMALE; FUNDUS OCULI; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS; MICE; MICE, INBRED BALB C; NANOPARTICLES; ORGAN SPECIFICITY; RETINAL PIGMENT EPITHELIUM;

MUS;

EID: 80053588027     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.08.062     Document Type: Article

References (46)

1. Hoffman E.A., Conley S.M., Stamer W.D., McKay B.S. Barriers to productive transfection of trabecular meshwork cells. Mol Vis 2005, 11:869-875.
2. Tros de Ilarduya C., Sun Y., Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 2010, 40(3):159-170.
3. Zhang S., Zhao Y., Zhao B., Wang B. Hybrids of nonviral vectors for gene delivery. Bioconjug Chem 2010, 21(6):1003-1009.
4. Liu G., Li D., Pasumarthy M.K., Kowalczyk T.H., Gedeon C.R., Hyatt S.L., et al. Nanoparticles of compacted DNA transfect postmitotic cells. J Biol Chem 2003, 278(35):32578-32586.
5. Cai X., Conley S.M., Nash Z., Fliesler S.J., Cooper M.J., Naash M.I. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010, 24(4):1178-1191.
6. Cai X., Nash Z., Conley S.M., Fliesler S.J., Cooper M.J., Naash M.I. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One 2009, 4(4):e5290.
7. Conley S.M., Naash M.I. Nanoparticles for retinal gene therapy. Prog Retin Eye Res 2010, 29(5):376-397.
8. Farjo R., Skaggs J., Quiambao A.B., Cooper M.J., Naash M.I. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006, 1:e38.
9. Yurek D.M., Fletcher A.M., Smith G.M., Seroogy K.B., Ziady A.G., Molter J., et al. Long-term transgene expression in the central nervous system using DNA nanoparticles. Mol Ther 2009, 17(4):641-650.
10. Ziady A.G., Gedeon C.R., Miller T., Quan W., Payne J.M., Hyatt S.L., et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003, 8(6):936-947.
11. Davis P.B., Cooper M.J. Vectors for airway gene delivery. AAPS J 2007, 9(1):E11-E17.
12. Yurek D.M., Flectcher A.M., Kowalczyk T.H., Padegimas L., Cooper M.J. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant 2009, 18(10):1183-1196.
13. Konstan M.W., Davis P.B., Wagener J.S., Hilliard K.A., Stern R.C., Milgram L.J., et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004, 15(12):1255-1269.
14. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005, 85(3):845-881.
15. Maeda A., Maeda T., Palczewski K. Improvement in rod and cone function in mouse model of Fundus albipunctatus after pharmacologic treatment with 9-cis-retinal. Invest Ophthalmol Vis Sci 2006, 47(10):4540-4546.
16. Redmond T.M., Poliakov E., Yu S., Tsai J.Y., Lu Z., Gentleman S. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A 2005, 102(38):13658-13663.
17. Senechal A., Humbert G., Surget M.O., Bazalgette C., Arnaud B., Arndt C., et al. Screening genes of the retinoid metabolism: novel LRAT mutation in leber congenital amaurosis. Am J Ophthalmol 2006, 142(4):702-704.
18. Xiao Q., Hartzell H.C., Yu K. Bestrophins and retinopathies. Pflugers Arch 2010, 460(2):559-569.
19. Hauswirth W.W., Aleman T.S., Kaushal S., Cideciyan A.V., Schwartz S.B., Wang L., et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19(10):979-990.
20. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358(21):2231-2239.
21. Maguire A.M., High K.A., Auricchio A., Wright J.F., Pierce E.A., Testa F., et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374(9701):1597-1605.
22. Maguire A.M., Simonelli F., Pierce E.A., Pugh E.N., Mingozzi F., Bennicelli J., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358(21):2240-2248.
23. Simonelli F., Maguire A.M., Testa F., Pierce E.A., Mingozzi F., Bennicelli J.L., et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010, 18(3):643-650.
24. Hirsch M.L., Agbandje-McKenna M., Samulski R.J. Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther 2010, 18(1):6-8.
25. Wu Z., Yang H., Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010, 18(1):80-86.
26. Fink T.L., Klepcyk P.J., Oette S.M., Gedeon C.R., Hyatt S.L., Kowalczyk T.H., et al. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther 2006, 13(13):1048-1051.
27. Peden C.S., Burger C., Muzyczka N., Mandel R.J. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004, 78(12):6344-6359.
28. Sun J.Y., Anand-Jawa V., Chatterjee S., Wong K.K. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003, 10(11):964-976.
29. Annear M.J., Bartoe J.T., Barker S.E., Smith A.J., Curran P.G., Bainbridge J.W., et al. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Ther 2011, 18(1):53-61.
30. Li Q., Miller R., Han P.Y., Pang J., Dinculescu A., Chiodo V., et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008, 14:1760-1769.
31. Ziady A.G., Gedeon C.R., Muhammad O., Stillwell V., Oette S.M., Fink T.L., et al. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther 2003, 8(6):948-956.
32. Ding X.Q., Quiambao A.B., Fitzgerald J.B., Cooper M.J., Conley S.M., Naash M.I. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One 2009, 4(10):e7410.
33. Esumi N., Oshima Y., Li Y., Campochiaro P.A., Zack D.J. Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem 2004, 279(18):19064-19073.
34. Chakraborty D., Conley S.M., Stuck M.W., Naash M.I. Differences in RDS trafficking, assembly and function in cones versus rods: insights from studies of C150S-RDS. Hum Mol Genet 2010, 19(24):4799-4812.
35. Bakall B., Marmorstein L.Y., Hoppe G., Peachey N.S., Wadelius C., Marmorstein A.D. Expression and localization of bestrophin during normal mouse development. Invest Ophthalmol Vis Sci 2003, 44(8):3622-3628.
36. Nour M., Quiambao A.B., Peterson W.M., Al-Ubaidi M.R., Naash M.I. P2Y(2) receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice. Invest Ophthalmol Vis Sci 2003, 44(10):4505-4514.
37. Mayerson P.L., Hall M.O. Rat retinal pigment epithelial cells show specificity of phagocytosis in vitro. J Cell Biol 1986, 103(1):299-308.
38. de Queiroz J.M., Blanks J.C., Ozler S.A., Alfaro D.V., Liggett P.E. Subretinal perfluorocarbon liquids. An experimental study. Retina 1992, 12(3 Suppl):S33-S39.
39. Chen X., Shank S., Davis P.B., Ziady A.G. Nucleolin-mediated cellular trafficking of DNA nanoparticle is lipid raft and microtubule dependent and can be modulated by glucocorticoid. Mol Ther 2011, 19(1):93-102.
40. Chen X., Kube D.M., Cooper M.J., Davis P.B. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol Ther 2008, 16(2):333-342.
41. Degiulio J.V., Kaufman C.D., Dean D.A. The SP-C promoter facilitates alveolar type II epithelial cell-specific plasmid nuclear import and gene expression. Gene Ther 2010, 17(4):541-549.
42. Miller A.M., Munkonge F.M., Alton E.W., Dean D.A. Identification of protein cofactors necessary for sequence-specific plasmid DNA nuclear import. Mol Ther 2009, 17(11):1897-1903.
43. Kong F., Li W., Li X., Zheng Q., Dai X. Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Exp Eye Res 2010, 90(5):546-554.
44. Kachi S., Binley K., Yokoi K., Umeda N., Akiyama H., Muramatu D., et al. Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization. Hum Gene Ther 2009, 20(1):31-39.
45. Read S.P., Cashman S.M., Kumar-Singh R. A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo. J Gene Med 2010, 12(1):86-96.
46. Kachi S., Oshima Y., Esumi N., Kachi M., Rogers B., Zack D.J., et al. Nonviral ocular gene transfer. Gene Ther 2005, 12(10):843-851.